文献速递白血病造血干细胞移植与细胞治疗

AML 移植前基因组 MRD 阳性者应选清髓性预处理

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
PubMed 文献 · J Clin Oncol · 2019-12-20

该 III 期临床试验对形态学完全缓解的髓系恶性肿瘤患者移植前血样行 13 基因超深度测序,随机比较清髓性(MAC)与减低强度(RIC)预处理。NGS 阳性患者中 MAC 较 RIC 显著降低复发、改善生存;NGS 阴性者两组生存相似。

要点

  • 移植前 NGS 可检出突变的 AML 患者,MAC 较 RIC 复发更低、生存更优。
  • NGS 未检出突变者,MAC 与 RIC 的 3 年 OS 相似。
  • NGS 阳性者中 RIC 与复发增加、无复发生存和 OS 下降独立相关。

核心结论

  • AML 患者移植前若基因组检测提示 MRD,选择 MAC 而非 RIC 可改善生存。

研究设计与样本

  • III 期临床试验随机分配成人形态学完全缓解的髓系恶性肿瘤患者至 MAC 或 RIC。
  • 对预处理前血样行 13 个 AML 常见突变基因的超深度纠错测序。

主要发现

  • MAC 受者 32%、RIC 受者 37% 未检出突变,两组 3 年 OS 为 56% 对 63%(P = .96)。
  • NGS 阳性者 MAC 与 RIC 的 3 年累积复发率为 19% 对 67%(P < .001)。
  • NGS 阳性者 MAC 与 RIC 的 3 年 OS 为 61% 对 43%(P = .02)。
  • NGS 阳性者多变量分析中,RIC 较 MAC 的复发 HR 为 6.38(95% CI 3.37–12.10,P < .001)。
  • NGS 阳性者中 RIC 较 MAC 的无复发生存 HR 为 2.94(95% CI 1.84–4.69,P < .001),OS HR 为 1.97(95% CI 1.17–3.30,P = .01)。

临床怎么用

  • AML 移植前应行基因组 MRD 检测,阳性者优先考虑 MAC 而非 RIC。
  • NGS 阴性者 MAC 与 RIC 生存相似,可结合其他因素个体化选择预处理强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status before alloHCT has been shown to be prognostic. Whether modulation of the intensity of the alloHCT conditioning regimen in patients with AML who test positive for MRD can prevent relapse and improve survival is unknown. METHODS: Ultra-deep, error-corrected sequencing for 13 commonly mutated genes in AML was performed on preconditioning blood from patients treated in a phase III clinical trial that randomly assigned adult patients with myeloid malignancy in morphologic complete remission to myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC). RESULTS: No mutations were detected in 32% of MAC and 37% of RIC recipients; these groups had similar survival (3-year overall survival [OS], 56% v 63%; P = .96). In patients with a detectable mutation (next-generation sequencing [NGS] positive), relapse (3-year cumulative incidence, 19% v 67%; P < .001) and survival (3-year OS, 61% v 43%; P = .02) was significantly different between the MAC and RIC arms, respectively. In multivariable analysis for NGS-positive patients, adjusting for disease risk and donor group, RIC was significantly associated with increased relapse (hazard ratio [HR], 6.38; 95% CI, 3.37 to 12.10; P < .001), decreased relapse-free survival (HR, 2.94; 95% CI, 1.84 to 4.69; P < .001), and decreased OS (HR, 1.97; 95% CI, 1.17 to 3.30; P = .01) compared with MAC. Models of AML MRD also showed benefit for MAC over RIC for those who tested positive. CONCLUSION: This study provides evidence that MAC rather than RIC in patients with AML with genomic evidence of MRD before alloHCT can result in improved survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hourigan CS, Dillon LW, Gui G, et al. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol. 2019. PMID: 31860405. doi:10.1200/JCO.19.03011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。